

[114] TURNING 'COLD' TUMOR INTO 'HOT' TUMOR - LESSONS FROM VB-111, A VIRAL IMMUNO-ONCOLOGY AGENT AND VB-611, A NOVEL BI-SPECIFIC ANTIBODY

Dror Harats, CEO, Vascular Biogenics Ltd Operated As VBL Therapeutics, Modiin, Israel

- **Investment Rational**
VBL Therapeutics is a NASDAQ-traded, late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of treatments for cancer. Our lead candidate, VB-111, is anti-cancer gene-therapy investigational drug, currently studied in a Phase 3 pivotal study in ovarian cancer, with potential across multiple solid tumors. We've signed a licensing deal for VB-111 in Japan, yet retain its rights elsewhere.
- **Business Strategy**
OVAL, our Phase 3 pivotal study for VB-111 in platinum-resistant ovarian cancer, is conducted in collaboration with the GOG Foundation, with interim analysis expected at year-end 2019. We have a strong pipeline, including our exciting MOSPD2 program for oncology and inflammatory indications, and the Lecinoxoids, our small molecules anti-inflammatory platform; collectively enabling internal development and external collaborations.
- **Core Technology**
VBL has pioneered the Vascular-Targeting-System, a first-in-class gene-therapy platform technology which enables systemic administration of genes to destroy or promote angiogenic blood vessels. VBL has also pioneered the MOSPD2-targeting biologics for Immune/Oncology applications and is developing the Lecinoxoids platform of anti-inflammatory small-molecules. Our novel three platform technologies were developed in-house, and have broad applicability supported by strong science and IP.
- **Product Profile/Pipeline**
Phase 3 asset VB-111 has received orphan-drug designation in the US and Europe, and fast-track designation in the US for rGBM. VB-111 has received an Orphan-Designation for the treatment of ovarian-cancer from the European Commission. Anti-inflammatory molecule VB-201 is Phase-2-ready with potential for treatment of NASH and chronic-immune-related diseases. Our VB-600 platform of mAbs is in development for inflammatory and oncology indications.
- **What's Next?**
We expect an interim analysis in the OVAL Phase 3 pivotal study in ovarian cancer at year-end 2019. Two additional phase 2 investigator-initiated trials are expected to launch in 2019. IND filings in the mAbs program are expected during 2020. VBL has a strong cash balance to support its programs into 2021.